ArticleDiabetes, obesity & metabolism2026

Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.

Rune Viig Overgaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.